Search results for "BREAST"

showing 10 items of 1871 documents

Nuclear and cytoplasmic interaction of pRb2/p130 and ER-β in MCF-7 breast cancer cells

2006

Estrogens exhibit important biological functions and influence several pathological processes of hormone-dependent diseases. The biological actions of estrogens require their interaction with two estrogen receptors (ER-alpha and ER-beta), which are ligand-dependent transcription factors. ER-alpha and ER-beta exhibit distinct tissue expression patterns as well as show different patterns of gene regulation. In addition, it has been suggested that ER-beta works as a counter partner of ER-alpha through inhibition of the transactivating functions of ER-alpha. For instance, ER-beta seems to play a different role in breast tumorigenesis than ER-alpha, as ER-beta decreased expression in breast canc…

OncologyCytoplasmmedicine.medical_specialtyMolecular Sequence DataEstrogen receptorBreast NeoplasmsEstrogen receptorsmedicine.disease_causeBreast cancerBreast cancerCancer stem cellCell Line TumorInternal medicinemedicineEstrogen Receptor betaHumansImmunoprecipitationGene silencingAmino Acid SequenceTranscription factorBreast cancer; Estrogen receptors; Estrogens; pRb2/130Cell NucleusRegulation of gene expressionRetinoblastoma-Like Protein p130business.industryEstrogensHematologymedicine.diseaseOncologyMCF-7Cancer researchbusinessCarcinogenesispRb2/130
researchProduct

Associations between aromatase CYP19 rs10046 polymorphism and breast cancer risk: from a case-control to a meta-analysis of 20,098 subjects.

2012

Lifetime exposure to estrogen is a factor that plays an important role in the pathogenesis and progression of breast cancer. Genetic variants in genes of the biosynthesis and metabolism of estrogen have been associated with breast cancer risk. Among them, the CYP19 gene encodes for aromatase, the enzyme that catalyzes the conversion of androgens to estrogens. The rs10046 polymorphism on the CYP19 gene has been related to levels of circulating estradiol and to the estradiol/testosterone ratio. To date, epidemiological studies of rs10046 have been performed in different populations with contradictory results. In the present study, we have conducted a case-control analysis (522 cases and 1221 …

OncologyEpidemiologylcsh:MedicineBreast TumorsAromataselcsh:ScienceAged 80 and overMultidisciplinarybiologyObstetrics and GynecologyMiddle AgedOncologyMeta-analysisMedicineFemaleCancer EpidemiologyResearch ArticleAdultmedicine.medical_specialtyAdolescentmedicine.drug_classBreast NeoplasmsPolymorphism Single NucleotideYoung AdultBreast cancerAromataseInternal medicineGenetic modelBreast CancermedicineGeneticsHumansGenetic Predisposition to DiseaseAlleleBiologyAgedPopulation Biologylcsh:RCase-control studyReproducibility of ResultsCancers and NeoplasmsOdds ratiomedicine.diseaseEndocrinologyEstrogenCase-Control Studiesbiology.proteinGenetic PolymorphismWomen's Healthlcsh:QPopulation GeneticsPLoS ONE
researchProduct

Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study

2019

Background: In real-world practice, eribulin mesylate provides significant survival benefit, with a manageable safety profile in heavily pretreated patients with metastatic breast cancer (MBC). Methods: In this prospective, open-label, multicentre, observational study we evaluated the effectiveness and tolerability of eribulin as third-line treatment in a homogeneous population. The primary endpoints were the safety profile and response in metastatic sites; secondary endpoints included the response in different subtypes, overall response rate (ORR), progression-free survival (PFS) and overall survival (OS). Results: From 2013 to 2016, 118 women were treated in 21 Sicilian institutions; the …

OncologyEribulin Mesylatemedicine.medical_specialtymulticentreThird-line therapylcsh:RC254-282chemistry.chemical_compoundInternal medicinemedicineIn patienteribulin metastatic breast cancer multicentre prospective real world third lineeribulinthird lineOriginal Researchbusiness.industryreal worldprospectivemedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensMetastatic breast cancerSafety profileSurvival benefitOncologychemistryObservational studymetastatic breast cancerbusinessEribulinTherapeutic Advances in Medical Oncology
researchProduct

Strong founder effects in BRCA1 mutation carrier breast cancer patients from Latvia

1999

Germ-line mutations of the BRCA1 gene account for approximately half of the cases of hereditary breast/ovarian cancers. We have screened index patients from 15 breast cancer families and 8 sporadic breast cancer patients from Latvia for mutations in all coding exons of the BRCA1 gene, using combined Heteroduplex Analysis/SSCP followed by direct sequencing of the variants. BRCA1 germ-line mutations proved to be frequent in Latvian breast cancer patients, also in moderate-risk families and sporadic patients. Out of 23 cases a total of 8 patients (35%) exhibited three different mutations (5382insC, C61G, 4153delA). Interestingly, these three recurrent mutations accounted for all mutations in o…

OncologyGeneticsmedicine.medical_specialtyMutationDirect sequencingSingle-strand conformation polymorphismBiologymedicine.diseasemedicine.disease_causeExonBreast cancerInternal medicineGeneticsmedicineGenetics (clinical)Brca1 geneFounder effectHeteroduplexHuman Mutation
researchProduct

Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer

2019

Background The role of the BARD1 gene in breast cancer (BC) and ovarian cancer (OC) predisposition remains elusive, as published case-control investigations have revealed controversial results. We aimed to assess the role of deleterious BARD1 germline variants in BC/OC predisposition in a sample of 4920 BRCA1/2-negative female BC/OC index patients of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). Methods A total of 4469 female index patients with BC, 451 index patients with OC, and 2767 geographically matched female control individuals were screened for loss-of-function (LoF) mutations and potentially damaging rare missense variants in BARD1. All patients met the …

OncologyGermline0302 clinical medicineLoss of Function MutationSurgical oncologyOdds RatioPrevalenceMissense mutation030212 general & internal medicineAge of Onset10. No inequalityExomeEarly onset breast cancerAged 80 and overOvarian NeoplasmsBARD1 GeneHigh-Throughput Nucleotide SequencingMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good health030220 oncology & carcinogenesisFemaleTechnology PlatformsResearch ArticleAdultmedicine.medical_specialtyAdolescentUbiquitin-Protein Ligases610Breast Neoplasmslcsh:RC254-282Young Adult03 medical and health sciencesGermline mutationBreast cancerOvarian cancerInternal medicinemedicineBARD1HumansGenetic Predisposition to DiseaseGermline mutationsGenetic Association StudiesGerm-Line MutationAgedbusiness.industryTumor Suppressor ProteinsOdds ratiomedicine.diseaseConfidence intervalBARD1; Early onset breast cancer; Germline mutations; Ovarian cancerOvarian cancerbusiness
researchProduct

Morphological and biomolecular characteristics of subcentimetric invasive breast carcinomas in Sicily: A multicentre retrospective study in relation …

2012

Little information from clinical trials is available regarding the efficacy of trastuzumab treatment in subcentimetric breast carcinomas (BCs). The aim of this study was to verify the existence of correlations between HER2 and hormone receptor status, Ki67 values, grade, histotype and node involvement in a cohort of pT1a,b BCs from an area not widely covered by screening campaigns. A total of 410 pT1a,b BC formalin-fixed paraffin-embedded samples collected from eight Sicilian Anatomo-Pathological Units (APUs) were classified according to the WHO classification and tumour grading was established. Estrogen and progesterone receptor status, Ki67 labelling index and HER2 status were available. …

OncologyGynecologyCancer Researchmedicine.medical_specialtybusiness.industryCancerRetrospective cohort studyArticlesProgesterone Receptor StatusSettore MED/08 - Anatomia Patologicamedicine.diseaseClinical trialBreast carcinoma immunohistochemistry HER2medicine.anatomical_structureOncologyTrastuzumabInternal medicineCohortsmall size breast cancer screening campaign staging immunohistochemistrymedicineBreast carcinomabusinessLymph nodemedicine.drug
researchProduct

Role of trastuzumab in infracentimetric HER2-positive breast cancer: The southern Italy experience.

2014

e11512 Background: HER2 positive (HER2+) disease is relatively uncommon in early infracentimetric breast cancer (BC) accounting for approximately 10% of cases. Trastuzumab (T) based-adjuvant therap...

OncologyGynecologyCancer Researchmedicine.medical_specialtybusiness.industryDiseasemedicine.diseaseBreast cancerOncologyTrastuzumabInternal medicineHER2 Positive Breast Cancermedicineskin and connective tissue diseasesbusinessneoplasmsmedicine.drugJournal of Clinical Oncology
researchProduct

Metastatic pattern of breast cancer according to immunohistochemical defined subtypes in the transitional phase of adjuvant trastuzumab treatment.

2014

e11581 Background: Prognosis of early breast cancer (BC) differs significantly upon subtypes (ST). Treatment with adjuvant trastuzumab improves outcome of HER2 overexpressing BC, however, less in k...

OncologyGynecologyCancer Researchmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentmedicine.diseaseTransitional phaseBreast cancerOncologyTrastuzumabInternal medicineMedicineImmunohistochemistryskin and connective tissue diseasesbusinessneoplasmsAdjuvantmedicine.drugEarly breast cancerJournal of Clinical Oncology
researchProduct

Basic and Clinical Relevance of Hormonal Influence in Breast Cancer

1990

In the Federal Republic of Germany breast cancer has a leading place among malignant tumors in women. Genital and breast cancers account for 32% of all female deaths from malignant neoplasias. The distribution of types of cancer is as follows: breast 52%, uterine cervix 9%, corpus uteri 4.5%, adnexae 19%, and other sex organs 15.5% (Maas and Sachs 1972; Schmidt-Matthiesen 1975, Vorherr 1980). Besides general epidemiological factors such as geographical distribution, dietary factors, age distribution, familial disposition, and socioeconomic influences, possible hormonal components are discussed in connection with the etiology of breast cancer (Fischedick and Lux 1977; Henderson et al. 1974; …

OncologyGynecologymedicine.medical_specialtybusiness.industryIncidence (epidemiology)Estrogen receptorCancermedicine.diseaseMenopauseBreast cancerInternal medicineEtiologyMedicineSex organRisk factorbusiness
researchProduct

Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts

2018

Source at https://doi.org/10.1186/s13058-018-1073-0. Licensed CC BY-NC-ND 4.0. Background: Few published breast cancer (BC) risk prediction models consider the heterogeneity of predictor variables between estrogen-receptor positive (ER+) and negative (ER-) tumors. Using data from two large cohorts, we examined whether modeling this heterogeneity could improve prediction. Methods: We built two models, for ER+ (ModelER+) and ER- tumors (ModelER-) , respectively, in 281,330 women (51% postmenopausal at recruitment) from the European Prospective Investigation into Cancer and Nutrition cohort. Discrimination (C-statistic) and calibration (the agreement between predicted and observed tumor risks)…

OncologyHORMONE-REPLACEMENT THERAPYmedicine.medical_treatmentWHI0302 clinical medicineBreast cancerRisk FactorsEstrogen receptor030212 general & internal medicineProspective StudiesProspective cohort study2. Zero hungerIncidenceHormone replacement therapy (menopause)Middle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisRisk prediction3. Good healthEuropean Prospective Investigation into Cancer and NutritionMenopausePOSTMENOPAUSAL WOMENReceptors EstrogenPLUS PROGESTIN030220 oncology & carcinogenesisCohortFemaleRisk assessmentResearch Articlemedicine.medical_specialtyMODELSAntineoplastic AgentsBreast NeoplasmsEstrògenslcsh:RC254-282Models BiologicalRisk AssessmentVALIDATIONCàncer de mamaMAMMOGRAPHY03 medical and health sciencesBreast cancerInternal medicinemedicineHumansOncology & CarcinogenesisCancer och onkologiVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762business.industryMORTALITYKirurgiProspective cohortmedicine.diseaseEstrogenVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762Cancer and OncologySurgerybusinessEPIC1112 Oncology And CarcinogenesisBody mass indexFollow-Up StudiesBreast Cancer Research : BCR
researchProduct